{"url_path":"/sec/inmb/8-k/2026-07-01/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1711754/0001213900-26-073983-index.html","accession_number":"0001213900-26-073983","cik":"0001711754","ticker":"INMB","issuer_name":"Inmune Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711754/0001213900-26-073983-index.html","primary_entity_key":"0001711754","primary_entity_name":"Inmune Bio, Inc."},"word_count":445,"has_tables":true,"body_markdown":"**Item 1.01 Entry into a Material Definitive Agreement.** \n\n \n\nOn June 30, 2026, INmune\nBio Inc. (the Company”) entered into a warrant inducement offer letter agreement (the “Inducement Letter”) and into\nan amendment to common stock purchase warrant (the “Second Amendment”) with certain holders (the “Holders”) of\ncommon stock purchase warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such\nwarrants were amended on December 22, 2025 (the “April 2024 Warrants”).\n\n \n\nPursuant to the Inducement\nLetter the Company offered the Holders the opportunity to exercise 50% of the April 2024 Warrants held by them for a reduced exercise\nprice per share equal to $1.40 (reduced from $1.95) (the “Reduced Exercise Price”) and to amend the April 2024 Warrants such\nthat the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised\npursuant to the Inducement Letter, shall be extended from June 30, 2026, to December 31, 2027.\n\n \n\nPursuant to the Inducement\nLetter, Holders agreed to exercise, for cash, 647,112 April 2024 Warrants, representing 50% of the April 2024 Warrants held by such Holders,\nand have agreed to purchase an aggregate of 647,112 shares of common stock at the Reduced Exercise Price in exchange for the Company’s\nagreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were\nnot exercised pursuant to the Inducement Letter, from June 30, 2026, to December 31, 2027. The Company expects to receive an aggregate\nof $905,957 as consideration for the exercise of the said 50% of the April 2024 Warrants.\n\n \n\nPursuant to the Second\nAmendment, the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised\npursuant to the Inducement Letter, was extended from June 30, 2026, to December 31, 2027.\n\n \n\nThe issuance, or resale,\nof shares of common stock underlying the April 2024 Warrant have been registered pursuant to an effective registration statement (File\nNo. 333-279036). The Registration Statement is currently effective and, upon exercise of 50% the April 2024 Warrant pursuant to Inducement\nLetter will be effective for the issuance or resale of the shares of common stock underlying the April 2024 Warrants, as applicable.\n\n \n\nThe foregoing summary\nof the Inducement Letter and the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the\nform of the Inducement Letter and the Second Amendment, a copy of which is filed as Exhibits 4.1 and 10.1 hereto and incorporated herein\nby reference."}